Up-and-coming generation has an “occupy healthcare” attitude and could advocate for Medicare for all by 2020.
The future of healthcare centers on scale, population health and the value of care rather than the volume of care, according to thought leaders speaking at a leadership briefing in November in Akron, Ohio. But the political atmosphere also adds layers of complexity, they say.
In order for health systems to thrive, they need to create partnerships that advance care not only as a clinical goal but as a business imperative, according to Thomas Strauss, president and CEO of Summa Health System. Larger institutions will have the economies of scale that are necessary in the new era that aims to transform volume to value.
For example, he says, as many as 40% of Summa patients in a recent clinic survey reported having a mental health issue. The data point underlines the need for patient centered medical homes to have embedded behavioral health professionals, but there’s no reimbursement for it. Beneficial clinical models that are not reimbursed often become unsustainable.
“We have to move to the total cost of care,” Strauss says.
And the clinical aspects are only the beginning. Under health reform, hospitals have added regulatory risk that can amount to millions. Strauss says for Summa, reform could create anywhere from $19 million to $90 million in impact per year. Increasing efficiency is one way to manage the financial implications.
Every year, 6% to 8% of an acute care hospital’s revenue is at risk for penalties from readmissions, inadequate vaccinations for hospital employees and fraud audits.
“It’s not just the reimbursement, it’s also the government speed traps,” he says.
Paul Keckley, independent healthcare consultant, says the Patient Protection and Affordable Care Act (PPACA) is an imperfect law that resulted from many iterations, and it fails to address the reality of the healthcare system. It was created to help stabilize the U.S. economy-healthcare is about 17% of GDP-but the current landscape is much different than what lawmakers assumed when PPACA was written.
The healthcare cost trend has been around 6%, while GDP is only growing at 2% and workers’ wages are growing at less than 2%. Keckley says it could be another two years before the economy begins to recover. PPACA wasn’t framed for such a sluggish economic situation.
Although reform regulations by and large target health insurers, many have performed well financially since the passage of PPACA, he says. However, incentives must change to drive payers toward spending what is appropriate for population health-rather than spending “as little as possible.”
Evidence-based medicine is one solution. Consider that $210 billion is spent every year on testing patients. Although $54 billion can be attributed to defensive medicine, another $150 billion can be attributed to the reimbursement incentives for clinicians to order more volumes of tests and receive reimbursement, according to Keckley.
But he warns that farther into the future the single-payer model could rise again. He says the up-and-coming generation has an “occupy healthcare” attitude and could advocate for Medicare for all by 2020. The question at that point would be whether the industry could survive on Medicare rates.
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen
35th World AIDS Day Marks 20 Years of PEPFAR: Challenges and Strategies to Combat HIV/AIDS
November 29th 2023PEPFAR, having invested $100 billion and saved 25 million lives in the global fight against HIV/AIDS, faces Congressional hurdles in its reauthorization due to abortion debates. Despite widespread support and no evidence of abortion-related activities, the legislative process is at a standstill. Members of PEPFAR and authors of a recent editorial stress the significance of PEPFAR and advocate for integrating behavioral and social science into healthcare programs to achieve UNAIDS targets and address barriers in HIV/AIDS testing and treatment.
Read More
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, had a discussion with William Shrank, M.D., a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California, about how artificial intelligence's role is improving healthcare, where we are today with value-based care and the ongoing efforts of reducing waste in the healthcare space for this episode of the "What's on Your Mind" podcast series.
Listen
Study Raises Concerns Over Insurance Barriers to HIV Prevention Medications
November 29th 2023Despite its efficacy, PrEP remains underutilized compared to the need for it. High costs are among the barriers to PrEP use, along with limited knowledge among clinicians, lack of health insurance, stigma, and underestimation of personal HIV risk.
Read More